US 12,409,156 B2
Stable aqueous hydroxycarbamide solution
Khunal Bhavsar, Wigston (GB); Michael Edge, Wigston (GB); Claire Hodkinson, Wigston (GB); Kelly Grant, Wigston (GB); Hussain Mulla, Wigston (GB); and Peter White, Wigston (GB)
Assigned to Nova Bio-Pharma Product Development LTD, Wigston (GB)
Appl. No. 17/055,332
Filed by Nova Bio-Pharma Product Development LTD, Wigston (GB)
PCT Filed May 17, 2019, PCT No. PCT/GB2019/051362
§ 371(c)(1), (2) Date Nov. 13, 2020,
PCT Pub. No. WO2019/220134, PCT Pub. Date Nov. 21, 2019.
Claims priority of application No. 1808013 (GB), filed on May 17, 2018.
Prior Publication US 2021/0220299 A1, Jul. 22, 2021
Int. Cl. A61K 31/17 (2006.01); A61K 9/08 (2006.01); A61K 47/02 (2006.01); A61K 47/14 (2017.01); A61K 47/26 (2006.01); A61K 47/36 (2006.01)
CPC A61K 31/17 (2013.01) [A61K 9/08 (2013.01); A61K 47/02 (2013.01); A61K 47/14 (2013.01); A61K 47/26 (2013.01); A61K 47/36 (2013.01)] 20 Claims
 
1. A stable aqueous hydroxycarbamide solution comprising:
an aqueous solution comprising a hydroxycarbamide, wherein, after the aqueous solution is stored for four weeks at a temperature of 25° C. and 60% RH, the aqueous solution comprises less than 0.5% w/v of carbamoyloxyurea, less than 0.1% w/v of hydroxylamine, and has an initial pH of between 6.5 and 6.7.